Philippe Gual is a research director in INSERM (France) and head of the team “Chronic liver diseases associated with obesity and alcohol” since 2008 at the Mediterranean Center for Molecular Medicine (C3M) (INSERM, France). He obtained his Ph.D. degree in Endocrinology (Marseille, France, 1997). His thesis (INSERM, Nice) and post-doctoral training (IRCC, Italy and then INSERM, France) focused mostly on obesity complications, insulin signaling, and receptor tyrosine kinases. Since 2008, his translational research has mainly been focusing on the identification and the study of markers/actors in the progression of chronic liver diseases (NAFLD, ALD). He has numerous publications (101 publications, h-index 45 on 11/2021) in Gastroenterology, J Hepatol., and Hepatology. His expertise in obesity complications is widely recognized, as illustrated by the numerous invitations to review grant proposals and scientific articles, thesis supervisory committees (30), and scientific boards (e.g., “French Association for the Study of the Liver" (2017-2019) and INSERM study section).
Philippe Gual is a research director in INSERM (France) and head of the team “Chronic liver diseases associated with obesity and alcohol” since 2008 at the Mediterranean Center for Molecular Medicine (C3M) (INSERM, France). He obtained his Ph.D. degree in Endocrinology (Marseille, France, 1997). His thesis (INSERM, Nice) and post-doctoral training (IRCC, Italy and then INSERM, France) focused mostly on obesity complications, insulin signaling, and receptor tyrosine kinases. Since 2008, his translational research has mainly been focusing on the identification and the study of markers/actors in the progression of chronic liver diseases (NAFLD, ALD). He has numerous publications (101 publications, h-index 45 on 11/2021) in Gastroenterology, J Hepatol., and Hepatology. His expertise in obesity complications is widely recognized, as illustrated by the numerous invitations to review grant proposals and scientific articles, thesis supervisory committees (30), and scientific boards (e.g., “French Association for the Study of the Liver" (2017-2019) and INSERM study section).